Top

Published in:

01-01-2011 | Review

The application of in vitro cell-free conversion systems to human prion diseases

Authors: Michael Jones, Alexander H. Peden, Mark W. Head, James W. Ironside

Published in: Acta Neuropathologica | Issue 1/2011

Abstract

A key event in the pathogenesis of prion diseases is the conversion of the normal cellular isoform of the prion protein into the disease-associated isoform, but the mechanisms operating in this critical event are not yet fully understood. A number of novel approaches have recently been developed to study factors influencing this process. One of these, the protein misfolding cyclical amplification (PMCA) technique, has been used to explore defined factors influencing the conversion of cellular prion protein in a cell-free model system. Although initially developed in animal models, this technique has been increasingly applied to human prion diseases. Recent studies have focused on the role of different isoforms of the disease-associated human prion protein and the effects of the naturally occurring polymorphism at codon 129 in the human prion protein gene on the conversion process, improving our understanding of the interaction between host and agent factors that influence the wide range of phenotypes in human prion diseases. This technique also allows a greatly enhanced sensitivity of detection of disease-associated prion protein in human tissues and fluids, which is potentially applicable to disease screening, particularly for variant Creutzfeldt–Jakob disease. The PMCA technique can also be used to model human susceptibility to a range of prions of non-human origin, which is likely to prove of considerable future interest as more novel and potentially pathogenic prion diseases are identified in animal species that form part of the human food chain.

Aguzzi A, Klein MA, Musahl C et al (1998) Use of brain grafts to study the pathogenesis of prion diseases. Essays Biochem 33:133–147PubMed

Aguzzi A, Sigurdson C, Heikenwalder M (2007) Molecular mechanisms of prion pathogenesis. Annu Rev Pathol

Asano M, Mohri S, Ironside JW et al (2006) vCJD prion acquires altered virulence through trans-species infection. Biochem Biophys Res Commun 342:293–299CrossRefPubMed

Atarashi R, Moore RA, Sim VL et al (2007) Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nat Methods 4:645–650CrossRefPubMed

Atarashi R, Wilham JM, Christensen L et al (2008) Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. Nat Methods 5:211–212CrossRefPubMed

Barria MA, Mukherjee A, Gonzalez-Romero D, Morales R, Soto C (2009) De novo generation of infectious prions in vitro produces a new disease phenotype. PLoS Pathog 5:e1000421CrossRefPubMed

Bessen RA, Kocisko DA, Raymond GJ et al (1995) Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature 375:698–700CrossRefPubMed

Bieschke J, Weber P, Sarafoff N et al (2004) Autocatalytic self-propagation of misfolded prion protein. Proc Natl Acad Sci USA 101:12207–12211CrossRefPubMed

Bishop MT, Hart P, Aitchison L et al (2006) Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 5:393–398CrossRefPubMed

10.

Bossers A, Belt PBGM, Raymond GJ et al (1997) Scrapie susceptibility-linked polymorphisms modulate the in vitro conversion of sheep prion protein to protease-resistant forms. Proc Natl Acad Sci USA 94:4931–4936CrossRefPubMed

11.

Bossers A, de Vries R, Smits MA (2000) Susceptibility of sheep for scrapie as assessed by in vitro conversion of nine naturally occurring variants of PrP. J Virol 74:1407–1414CrossRefPubMed

12.

Brandner S, Isenmann S, Raeber A et al (1996) Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379:339–343CrossRefPubMed

13.

Brandner S, Raeber A, Sailer A et al (1996) Normal host prion protein (PrPC) is required for scrapie spread within the central nervous system. Proc Natl Acad Sci USA 93:13148–13151CrossRefPubMed

14.

Bruce ME, Will RG, Ironside JW et al (1997) Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 389:498–501CrossRefPubMed

15.

Budka H, Head MW, Ironside JW et al (2003) Sporadic Creutzfeldt–Jakob disease. In: Dickson DW et al (eds) Neurodegeneration: the molecular pathology of dementia and movement disorders. ISN Neuropath Press, Basel, pp 287–297

16.

Buschmann A, Gretzschel A, Biacabe AG et al (2006) Atypical BSE in Germany—proof of transmissibility and biochemical characterization. Vet Microbiol 117:103–116CrossRefPubMed

17.

Cali I, Castellani R, Alshekhlee A et al (2009) Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt–Jakob disease: its effect on the phenotype and prion-type characteristics. Brain 132:2643–2658CrossRefPubMed

18.

Castilla J, Morales R, Saa P et al (2008) Cell-free propagation of prion strains. EMBO J 27:2557–2566CrossRefPubMed

19.

Castilla J, Saa P, Hetz C, Soto C (2005) In vitro generation of infectious scrapie prions. Cell 121:195–206CrossRefPubMed

20.

Castilla J, Saa P, Morales R et al (2006) Protein misfolding cyclic amplification for diagnosis and prion propagation studies. Methods Enzymol 412:3–21CrossRefPubMed

21.

Castilla J, Saa P, Soto C (2005) Detection of prions in blood. Nat Med 11:982–985PubMed

22.

Caughey B, Baron GS (2006) Prions and their partners in crime. Nature 443:803–810CrossRefPubMed

23.

Caughey B, Horiuchi M, Demaimay R, Raymond GJ (1999) Assays of protease-resistant prion protein and its formation. Methods Enzymol 309:122–133CrossRefPubMed

24.

Caughey B, Kocisko DA, Raymond GJ, Lansbury PT Jr (1995) Aggregates of scrapie-associated prion protein induce the cell-free conversion of protease-sensitive prion protein to the protease-resistant state. Chem Biol 2:807–817CrossRefPubMed

25.

Caughey B, Raymond GJ, Kocisko DA, Lansbury PT Jr (1997) Scrapie infectivity correlates with converting activity, protease resistance, and aggregation of scrapie-associated prion protein in guanidine denaturation studies. J Virol 71:4107–4110PubMed

26.

Caughey WS, Raymond LD, Horiuchi M, Caughey B (1998) Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci USA 95:12117–12122CrossRefPubMed

27.

Chabry J, Caughey B, Chesebro B (1998) Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides. J Biol Chem 273:13203–13207CrossRefPubMed

28.

Chabry J, Priola SA, Wehrly K et al (1999) Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol 73:6245–6250PubMed

29.

Chakrabarti O, Ashok A, Hegde RS (2009) Prion protein biosynthesis and its emerging role in neurodegeneration. Trends Biochem Sci 34:287–295CrossRefPubMed

30.

Chen PY, Lin CC, Chang YT, Lin SC, Chan SI (2002) One O-linked sugar can affect the coil-to-beta structural transition of the prion peptide. Proc Natl Acad Sci USA 99:12633–12638CrossRefPubMed

31.

Colby DW, Giles K, Legname G et al (2009) Design and construction of diverse mammalian prion strains. Proc Natl Acad Sci USA 106:20417–20422CrossRefPubMed

32.

Colby DW, Zhang Q, Wang S et al (2007) Prion detection by an amyloid seeding assay. Proc Natl Acad Sci USA 104:20914–20919CrossRefPubMed

33.

Collinge J, Clarke AR (2007) A general model of prion strains and their pathogenicity. Science 318:930–936CrossRefPubMed

34.

DebBurman SK, Raymond GJ, Caughey B, Lindquist S (1997) Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci USA 94:13938–13943CrossRefPubMed

35.

Deleault NR, Harris BT, Rees JR, Supattapone S (2007) From the cover: formation of native prions from minimal components in vitro. Proc Natl Acad Sci USA 104:9741–9746CrossRefPubMed

36.

Demaimay R, Harper J, Gordon H et al (1998) Structural aspects of Congo red as an inhibitor of protease-resistant prion protein formation. J Neurochem 71:2534–2541CrossRefPubMed

37.

Eiden M, Palm GJ, Hinrichs W et al (2006) Synergistic and strain-specific effects of bovine spongiform encephalopathy and scrapie prions in the cell-free conversion of recombinant prion protein. J Gen Virol 87:3753–3761CrossRefPubMed

38.

Gambetti P, Kong Q, Zou W, Parchi P, Chen SG (2003) Sporadic and familial CJD: classification and characterisation. Br Med Bull 66:213–239CrossRefPubMed

39.

Green KM, Castilla J, Seward TS et al (2008) Accelerated high fidelity prion amplification within and across prion species barriers. PLoS Pathog 4:e1000139PubMed

40.

Head MW, Bunn TJ, Bishop MT et al (2004) Prion protein heterogeneity in sporadic but not variant Creutzfeldt–Jakob disease: UK cases 1991–2002. Ann Neurol 55:851–859CrossRefPubMed

41.

Herrmann LM, Caughey B (1998) The importance of the disulfide bond in prion protein conversion. Neuroreport 9:2457–2461CrossRefPubMed

42.

Hill AF, Antoniou M, Collinge J (1999) Protease-resistant prion protein produced in vitro lacks detectable infectivity. J Gen Virol 80(Pt 1):11–14PubMed

43.

Horiuchi M, Priola SA, Chabry J, Caughey B (2000) Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci USA 97:5836–5841CrossRefPubMed

44.

Iniguez V, McKenzie D, Mirwald J, Aiken J (2000) Strain-specific propagation of PrP(Sc) properties into baculovirus-expressed hamster PrP(C). J Gen Virol 81:2565–2571PubMed

45.

Ironside JW, Bishop MT, Connolly K et al (2006) Variant Creutzfeldt–Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. Br Med J 332:1186–1188CrossRef

46.

Ironside JW, Ghetti B, Head MW, Piccardo P, Will RG (2008) Prion diseases. In: Love S, Louis DN, Ellison DW (eds) Hodder and Arnold, pp 1197–1273

47.

Ironside JW, Ritchie DL, Head MW (2005) Phenotypic variability in human prion diseases. Neuropathol Appl Neurobiol 31:565–579CrossRefPubMed

48.

Jackson GS, Hosszu LL, Power A et al (1999) Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science 283:1935–1937CrossRefPubMed

49.

Jones M, Peden A, Prowse C et al (2007) In vitro amplification and detection of variant Creutzfeldt–Jakob disease PrP(Sc). J Pathol 213:21–26CrossRefPubMed

50.

Jones M, Peden AH, Wight D et al (2008) Effects of human PrPSc type and PRNP genotype in an in vitro conversion assay. Neuroreport 19:1783–1786CrossRefPubMed

51.

Jones M, Peden AH, Yull H et al (2008) Human platelets as a substrate source for the in vitro amplification of the abnormal prion protein (PrP) associated with variant Creutzfeldt–Jakob disease. Transfusion 49:376–384CrossRefPubMed

52.

Jones M, Wight D, Barron R et al (2009) Molecular model of prion transmission to humans. Emerg Infect Dis 15:2013–2016CrossRefPubMed

53.

Kaneko K, Ball HL, Wille H et al (2000) A synthetic peptide initiates Gerstmann–Straussler–Scheinker (GSS) disease in transgenic mice. J Mol Biol 295:997–1007CrossRefPubMed

54.

Kaski D, Mead S, Hyare H et al (2009) Variant CJD in an individual heterozygous for PRNP codon 129. Lancet 374:2128CrossRefPubMed

55.

Kim JI, Cali I, Surewicz K et al (2010) Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors. J Biol Chem 285:14083–14087CrossRefPubMed

56.

Kirby L, Birkett CR, Rudyk H, Gilbert IH, Hope J (2003) In vitro cell-free conversion of bacterial recombinant PrP to PrPres as a model for conversion. J Gen Virol 84:1013–1020CrossRefPubMed

57.

Klohn PC, Stoltze L, Flechsig E, Enari M, Weissmann C (2003) A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc Natl Acad Sci USA 100:11666–11671CrossRefPubMed

58.

Kocisko DA, Come JH, Priola SA et al (1994) Cell-free formation of protease-resistant prion protein. Nature 370:471–474CrossRefPubMed

59.

Kocisko DA, Priola SA, Raymond GJ et al (1995) Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci USA 92:3923–3927CrossRefPubMed

60.

Kong Q, Zheng M, Casalone C et al (2008) Evaluation of the human transmission risk of an atypical bovine spongiform encephalopathy prion strain. J Virol 82:3697–3701CrossRefPubMed

61.

Kuczius T, Koch R, Keyvani K et al (2007) Regional and phenotype heterogeneity of cellular prion proteins in the human brain. Eur J Neurosci 25:2649–2655CrossRefPubMed

62.

Kurt TD, Perrott MR, Wilusz CJ et al (2007) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81:9605–9608CrossRefPubMed

63.

Legname G, Baskakov IV, Nguyen HO et al (2004) Synthetic mammalian prions. Science 305:673–676CrossRefPubMed

64.

Makarava N, Baskakov IV (2008) The same primary structure of the prion protein yields two distinct self-propagating states. J Biol Chem 283:15988–15996CrossRefPubMed

65.

Makarava N, Kovacs GG, Bocharova O et al (2010) Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol 119:177–187CrossRefPubMed

66.

Makarava N, Ostapchenko VG, Savtchenko R, Baskakov IV (2009) Conformational switching within individual amyloid fibrils. J Biol Chem 284:14386–14395CrossRefPubMed

67.

Mallucci G, Dickinson A, Linehan J et al (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302:871–874CrossRefPubMed

68.

Mallucci GR, White MD, Farmer M et al (2007) Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 53:325–335CrossRefPubMed

69.

Manson JC, Cancellotti E, Hart P, Bishop MT, Barron RM (2006) The transmissible spongiform encephalopathies: emerging and declining epidemics. Biochem Soc Trans 34:1155–1158CrossRefPubMed

70.

Mays CE, Titlow W, Seward T, Telling GC, Ryou C (2009) Enhancement of protein misfolding cyclic amplification by using concentrated cellular prion protein source. Biochem Biophys Res Commun 388:306–310CrossRefPubMed

71.

Murayama Y, Yoshioka M, Okada H et al (2007) Urinary excretion and blood level of prions in scrapie-infected hamsters. J Gen Virol 88:2890–2898CrossRefPubMed

72.

Nandi PK, Leclerc E, Nicole JC, Takahashi M (2002) DNA-induced partial unfolding of prion protein leads to its polymerisation to amyloid. J Mol Biol 322:153–161CrossRefPubMed

73.

Nishina KA, Deleault NR, Mahal SP et al (2006) The stoichiometry of host PrPC glycoforms modulates the efficiency of PrPSc formation in vitro. Biochemistry 45:14129–14139CrossRefPubMed

74.

Orru CD, Wilham JM, Hughson AG et al (2009) Human variant Creutzfeldt–Jakob disease and sheep scrapie PrP(res) detection using seeded conversion of recombinant prion protein. Protein Eng Des Sel 22:515–521CrossRefPubMed

75.

Parchi P, Giese A, Capellari S et al (1999) Classification of sporadic Creutzfeldt–Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46:224–233CrossRefPubMed

76.

Peden A, McCardle L, Head MW et al. (2010) Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia

77.

Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364:527–529CrossRefPubMed

78.

Post K, Pitschke M, Schafer O et al (1998) Rapid acquisition of beta-sheet structure in the prion protein prior to multimer formation. Biol Chem 379:1307–1317CrossRefPubMed

79.

Priola SA, Lawson VA (2001) Glycosylation influences cross-species formation of protease-resistant prion protein. EMBO J 20:6692–6699CrossRefPubMed

80.

Prusiner SB (1998) Prions. Proc Natl Acad Sci USA 95:13363–13383CrossRefPubMed

81.

Qin K, Yang DS, Yang Y et al (2000) Copper(II)-induced conformational changes and protease resistance in recombinant and cellular PrP. Effect of protein age and deamidation. J Biol Chem 275:19121–19131CrossRefPubMed

82.

Raymond GJ, Hope J, Kocisko DA et al (1997) Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature 388:285–288CrossRefPubMed

83.

Saa P, Castilla J, Soto C (2006) Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J Biol Chem 281:35245–35252CrossRefPubMed

84.

Saborio GP, Permanne B, Soto C (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411:810–813CrossRefPubMed

85.

Saborio GP, Soto C, Kascsak RJ et al (1999) Cell-lysate conversion of prion protein into its protease-resistant isoform suggests the participation of a cellular chaperone. Biochem Biophys Res Commun 258:470–475CrossRefPubMed

86.

Sarafoff NI, Bieschke J, Giese A et al (2005) Automated PrPres amplification using indirect sonication. J Biochem Biophys Methods 63:213–221CrossRefPubMed

87.

Sigurdson CJ, Nilsson KP, Hornemann S et al (2009) De novo generation of a transmissible spongiform encephalopathy by mouse transgenesis. Proc Natl Acad Sci USA 106:304–309CrossRefPubMed

88.

Soto C, Anderes L, Suardi S et al (2005) Pre-symptomatic detection of prions by cyclic amplification of protein misfolding. FEBS Lett 579:638–642CrossRefPubMed

89.

Tattum MH, Jones S, Pal S, Collinge J, Jackson GS (2010) Discrimination between prion-infected and normal blood samples by protein misfolding cyclic amplification. Transfusion 50:996–1002CrossRefPubMed

90.

Thorne L, Terry LA (2008) In vitro amplification of PrPSc derived from the brain and blood of sheep infected with scrapie. J Gen Virol 89:3177–3184CrossRefPubMed

91.

Uro-Coste E, Cassard H, Simon S et al (2008) Beyond PrP res type 1/type 2 dichotomy in Creutzfeldt–Jakob disease. PLoS Pathog 4:e1000029CrossRef

92.

Wang F, Wang X, Yuan CG, Ma J (2010) Generating a prion with bacterially expressed recombinant prion protein. Science 327:1132–1135CrossRefPubMed

93.

Webb PR, Powell L, Denyer M et al (2009) A retrospective immunohistochemical study reveals atypical scrapie has existed in the United Kingdom since at least 1987. J Vet Diagn Invest 21:826–829PubMed

94.

Weissmann C, Bueler H, Fischer M, Sauer A, Aguet M (1994) Susceptibility to scrapie in mice is dependent on PrPC. Philos Trans R Soc Lond B Biol Sci 343:431–433CrossRefPubMed

95.

Westergard L, Christensen HM, Harris DA (2007) The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta 1772:629–644PubMed

96.

White MD, Farmer M, Mirabile I et al (2008) Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci USA 105:10238–10243CrossRefPubMed

97.

Will RG, Ironside JW, Zeidler M et al (1996) A new variant of Creutzfeldt–Jakob disease in the UK. Lancet 347:921–925CrossRefPubMed

98.

Xiong LW, Raymond LD, Hayes SF, Raymond GJ, Caughey B (2001) Conformational change, aggregation and fibril formation induced by detergent treatments of cellular prion protein. J Neurochem 79:669–678CrossRefPubMed

99.

Zou WQ, Cashman NR (2002) Acidic pH and detergents enhance in vitro conversion of human brain PrPC to a PrPSc-like form. J Biol Chem 277:43942–43947CrossRefPubMed

Title: The application of in vitro cell-free conversion systems to human prion diseases
Authors: Michael Jones
Alexander H. Peden
Mark W. Head
James W. Ironside
Publication date: 01-01-2011
Publisher: Springer-Verlag
Published in: Acta Neuropathologica / Issue 1/2011
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-010-0708-8

2024 ASCO Annual Meeting

Springer Medicine

The application of in vitro cell-free conversion systems to human prion diseases

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Molecular biology and pathology of prion strains in sporadic human prion diseases

Cellular and sub-cellular pathology of animal prion diseases: relationship between morphological changes, accumulation of abnormal prion protein and clinical disease

Molecular pathology of human prion disease

Tau, prions and Aβ: the triad of neurodegeneration

Genetic Creutzfeldt-Jakob disease associated with the E200K mutation: characterization of a complex proteinopathy

Genetic Creutzfeldt–Jakob disease and fatal familial insomnia: insights into phenotypic variability and disease pathogenesis